Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Last updated: December 5, 2024
Sponsor: National Institute on Drug Abuse (NIDA)
Overall Status: Active - Recruiting

Phase

3

Condition

Stimulant Use Disorder

Treatment

iPLB

extended release bupropion (BUP-XL) tablets (BUP-XL)

extended-release naltrexone (XR-NTX)

Clinical Study ID

NCT06233799
NIDA/VA CS #1036
  • Ages 18-65
  • All Genders

Study Summary

The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Is 18 to 65 years of age;

  2. Meets DSM-5 criteria for moderate or severe MUD (4 or more criteria);

  3. Is interested in reducing or stopping MA use;

  4. Is able to speak English sufficiently to understand the study procedures and providewritten informed consent to participate in the study;

  5. Self-reports MA use on 18 or more days in the 30-day period prior to consent usingthe Timeline Followback (TLFB);

  6. Provides at least 2 urine samples positive for MA out of up to 3 tests, which willoccur at least 2 days apart within a 10-day period;

  7. If assigned as female at birth and/or currently has a uterus, is not pregnant,agrees to use acceptable birth control methods, and have periodic urine pregnancytesting done during participation in the study unless documentation of hysterectomyprovided;

  8. Is not physically dependent on opioids and meets subjective and objective measuresof being opioid-free prior to naltrexone injection per study medical clinician'sdetermination, including, if clinically required, a negative naloxone challenge;

  9. Is willing to comply with all study procedures and medication instructions;

  10. Agrees to use a smartphone app (downloaded for free to own device or on a studyprovided smartphone device) to take daily videos of medication dosing.

Exclusion

Exclusion Criteria:

  1. Has an acute medical or psychiatric disorder that would, in the judgment of thestudy medical clinician, make participation difficult or unsafe;

  2. Has suicidal or homicidal ideation that requires immediate attention;

  3. Has a history of epilepsy, seizure disorder, or head trauma with neurologicalsequelae (e.g., loss of consciousness that required hospitalization); currentanorexia nervosa or bulimia; or any other conditions that increase seizure risk inthe opinion of the study medical clinician;

  4. Has evidence of second or third degree heart block, atrial fibrillation, atrialflutter, prolongation of the QTc, or any other finding on the screening ECG that, inthe opinion of the study medical clinician, would preclude safe participation in thestudy;

  5. Has Stage 2 hypertension as determined by the study medical clinician (e.g., greaterthan or equal to 160/100 in 2 out of 3 readings during screening);

  6. Has any elevated bilirubin test value per laboratory criteria OR any other liverfunction test (LFT) value > 5 times the upper limit of normal per laboratorycriteria;

  7. Has a platelet count <100 x 10exp3/microliter;

  8. Has a body habitus that precludes gluteal intramuscular injection of XR-NTX inaccordance with the administration equipment (needle) and procedures;

  9. Has a known allergy or sensitivity to bupropion, naloxone, naltrexone, PLG (polyactideco-glycolide), carboxymethylcellulose or any other component of theXR-NTX diluents;

  10. Has been in a prior study of pharmacological or behavioral treatment for MUD within 6 months of study consent;

  11. Has taken an investigational drug in another study within 30 days of study consent;

  12. Has been prescribed and taken naltrexone or bupropion within 30 days of studyconsent;

  13. Is concurrently enrolled in formal behavioral or pharmacological Substance UseDisorder (SUD) treatment services;

  14. Is receiving ongoing treatment with tricyclic antidepressants, xanthines (i.e.,theophylline and aminophylline), systemic corticosteroids, nelfinavir, efavirenz,chlorpromazine, MAOIs, central nervous system stimulants (e.g., Adderall, Ritalin,etc.), or any medication that, in the judgment of the study medical clinician, couldinteract adversely with study medications;

  15. Has a current pattern of alcohol, benzodiazepine, or other sedative hypnotic usewhich would preclude safe participation in the study as determined by the studymedical clinician;

  16. Requires treatment with opioid-containing medications (e.g., opioid analgesics)during the study period;

  17. Has a surgery planned or scheduled during the study period;

  18. Is currently in jail, prison or any inpatient overnight facility as required bycourt of law or have pending legal action or other situation (e.g., unstable livingarrangements) that could prevent participation in the study or in any studyactivities;

  19. If assigned as female at birth and/or currently has a uterus, is currently pregnant,breastfeeding, or planning on conception.

Study Design

Total Participants: 360
Treatment Group(s): 4
Primary Treatment: iPLB
Phase: 3
Study Start date:
July 01, 2024
Estimated Completion Date:
April 30, 2027

Study Description

This is a double-blind, placebo-controlled, randomized clinical trial in which 360 individuals with moderate or severe MUD will be randomly assigned at a 1:1 ratio to receive either 1) extended release naltrexone (XR-NTX; as Vivitrol®) plus once daily oral extended release bupropion (BUP-XL) tablets (the XR-NTX/BUP-XL group) or 2) both the matching injection placebo (iPLB) and once daily oral placebo (oPLB) tablets (the iPLB/oPLB group). The study intervention consists of a 12-week treatment phase. It is hypothesized that the XR-NTX/BUP-XL arm will be associated with a greater number of "responders," defined as participants who provide at least 3 MA-negative urine drug screens (UDS) out of 4 samples obtained during the evaluation period (i.e., Weeks 11-12) of the 12-week long treatment phase, relative to the iPLB/oPLB arm. Secondary objectives include evaluating the effect of the extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) arm compared to the iPLB/oPLB arm on safety, other substance use outcomes, depression scores, quality of life, overall functioning, clinic attendance, and medication adherence.

Connect with a study center

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas 72205
    United States

    Active - Recruiting

  • University of California Los Angeles

    Los Angeles, California 90038
    United States

    Active - Recruiting

  • University of California at San Diego

    San Diego, California 92037
    United States

    Active - Recruiting

  • Indiana University

    Indianapolis, Indiana 46202
    United States

    Active - Recruiting

  • University of Minnesota

    Minneapolis, Minnesota 55415
    United States

    Active - Recruiting

  • CODA

    Portland, Oregon 97214
    United States

    Active - Recruiting

  • MUSC/BHS

    Pickens, South Carolina 29671
    United States

    Active - Recruiting

  • University of Tennessee

    Memphis, Tennessee 38119
    United States

    Active - Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas 75247
    United States

    Active - Recruiting

  • University of Virginia

    Charlottesville, Virginia 22903
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.